Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Pancreatic cancer reprograms nerve cells to fuel growth

Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) in their current publication in Nature.

17 Feb 2025

2024 CSCO Breast Cancer guidelines revolutionize treatment approaches in China

Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.

14 Feb 2025

Triple-drug chemo fails to improve survival in advanced biliary tract cancer

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology showed that chemotherapy combining three different types of drugs did not improve overall survival for patients with advanced stage, inoperable biliary tract cancers.

17 Jan 2025

Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of high-grade serous ovarian cancer (HGSOC). By assessing metabolic activity, it also identifies early and variable responses to chemotherapy, improving precision in treatment strategies.

10 Dec 2024

Cetuximab performs better than durvalumab in treating head and neck cancers

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.

22 Nov 2024

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months.

19 Nov 2024

Short course chemotherapy boosts survival rates in cervical cancer patients

Cervical cancer patients were significantly more likely to be alive and cancer-free after five years when given a short course of chemotherapy prior to chemoradiation, finds a clinical trial led by researchers from UCL and UCLH.

15 Oct 2024

Extrachromosomal DNA in more aggressive cancers could be targets for future therapies

Research published in Nature Genetics on Oct.14, by Yale Cancer Center researchers at Yale School of Medicine, found a higher concentration of a specific kind of DNA — extrachromosomal or ecDNA — in more aggressive and advanced cancers that could mark them as targets for future therapies.

15 Oct 2024

TCT 2024 to feature latest advances in interventional cardiovascular medicine

The Cardiovascular Research Foundation is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.

28 Aug 2024

Multimodal therapy shows promise for cancer treatment

Cancer remains one of the most challenging diseases to treat due to its complexity and tendency to metastasize (spread into or invade, nearby tissues or distant places in the body to form new tumors). Traditional therapies, such as chemotherapy and radiation, often face limitations like non-specific targeting and severe side effects. In response, researchers are turning to innovative approaches that combine multiple therapeutic modalities to address these issues. This study explores a cutting-edge solution involving CNHs to create a multimodal cancer phototheranostic platform integrating photothermal therapy (PTT), immunotherapy, and chemotherapy.

23 Aug 2024

Study confirms high success rates of combined chemotherapy in treating testicular cancer

A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails.

19 Jul 2024

Innovative technique speeds up search for antimicrobial drug candidates

A method to screen a wide variety of drug candidates without laborious purification steps could advance the fight against drug-resistant bacteria.

11 Jul 2024

New tool predicts nerve damage risk from breast cancer treatment

Many women treated for breast cancer using taxanes, a type of cytostatic drug, often experience side effects in the nervous system.

8 Jul 2024

Paclitaxel treatment found to directly promote HBV replication and transcription

Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy.

24 Apr 2024

Drug-coated balloon shows superiority in coronary in-stent restenosis treatment

In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.

11 Mar 2024

Developing a prognostic model for bladder urothelial cancer using oxidative stress signatures

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 3, entitled, "Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures."

28 Feb 2024

IPIAD augments standard therapy for pancreatic ductal adenocarcinoma

A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, "IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone."

9 Feb 2024

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM.

13 Nov 2023

Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy at this disease stage or developed disease recurrence early after adjuvant chemotherapy.

31 Oct 2023